Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in August 2020 in response to the "at-risk" launch of a generic version of Metoject.
安大略省多伦多和伊利诺伊州芝加哥--(Newsfile Corp.,2024年5月1日)——继2023年1月的审判之后,加拿大联邦法院发布了一项判决,拒绝维持Metoject的加拿大专利。Medexus Pharmicals(多伦多证券交易所股票代码:MDP)(OTCQX:MEDXF)和Medexus向Metoject授予商业化权的许可方medex选择不对初审法院的裁决提出上诉。Medexus和medac于2020年8月提起诉讼,以回应Metoject仿制药的 “风险” 推出。
"While this outcome is disappointing, Metoject has weathered the sustained generic competition well since 2020," commented Richard Labelle, Medexus's General Manager—Canadian Operations. "We previously adjusted our commercialization strategy and so this court decision will result in no meaningful changes to our business."
Medexus加拿大运营总经理理查德·拉贝尔评论说:“尽管这一结果令人失望,但自2020年以来,Metoject一直经受住了持续的仿制药竞争。”“我们之前调整了商业化战略,因此法院的这一裁决不会给我们的业务带来任何有意义的变化。”
"We expect this outcome to have a limited impact on the company and the product," added Ken d'Entremont, Medexus's Chief Executive Officer. "We look forward to putting this litigation behind us and continuing to work on expanding and enhancing our business overall."
Medexus首席执行官肯·德恩特蒙特补充说:“我们预计这一结果对公司和产品的影响有限。”“我们期待将这起诉讼抛在脑后,继续努力扩大和增强我们的整体业务。”
The public judgment and reasons dated March 26, 2024 containing the full text of the trial court decision is available on the "Decisions of the Federal Court" section of the Federal Court's website.
包含初审法院裁决全文的2024年3月26日公开判决和理由可在联邦法院网站的 “联邦法院裁决” 部分查阅。
About Medexus
关于 Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at and its filings on SEDAR+ at .
Medexus是一家领先的特种制药公司,拥有强大的北美商业平台以及不断增长的创新和罕见病治疗解决方案组合。Medexus目前的重点是肿瘤学、血液学、风湿病、自身免疫性疾病、过敏和皮肤病学等治疗领域。有关Medexus及其产品组合的更多信息,请访问该公司的公司网站及其在SEDAR+上的文件,网址为。
Contacts
联系人
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Ken d'entremont | Medexus 制药首席执行官
电话:905-676-0003 | 电子邮件:ken.dentremont@medexus.com
Marcel Konrad | CFO, Medexus Pharmaceuticals
Tel: 312-548-3139 | Email: marcel.konrad@medexus.com
马塞尔·康拉德 | Medexus 制药首席财务官
电话:312-548-3139 | 电子邮件:marcel.konrad@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
维多利亚·卢瑟福 | 阿德莱德资本
电话:480-625-5772 | 电子邮件:victoria@adcap.ca
Forward-looking statements
前瞻性陈述
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. Specific forward-looking statements in this news release include, but are not limited to, statements regarding: expectations with respect to the impact of the Federal Court judgment on Metoject, the company, and its business. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments, and, in particular, Medexus's analysis and assessment of the market in which Metoject competes. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that, although the assumptions are believed to be reasonable in the circumstances, these risks and uncertainties mean that actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
本新闻稿中的某些陈述包含适用证券法所指的前瞻性信息,也称为和/或称为 “前瞻性信息” 或 “前瞻性陈述”。“预期”、“相信”、“期望”、“将”、“计划”、“潜力” 等词语以及类似的词语、短语或表述通常用于识别前瞻性陈述,尽管并非所有前瞻性陈述都包含这些识别词、短语或表达方式。本新闻稿中的具体前瞻性陈述包括但不限于有关以下方面的陈述:对联邦法院判决对Metoject、公司及其业务的影响的预期。这些陈述基于在得出结论或做出预测或预测时适用的因素或假设,包括基于历史趋势、当前状况和预期未来发展的假设,尤其是Medexus对Metoject竞争市场的分析和评估。由于前瞻性陈述与未来事件和状况有关,因此就其本质而言,它们需要做出假设,并涉及固有的风险和不确定性。Medexus警告说,尽管人们认为这些假设在这种情况下是合理的,但这些风险和不确定性意味着实际结果可能与前瞻性陈述所设想的预期有所不同,甚至可能存在重大差异。重大风险因素包括但不限于Medexus不时向加拿大证券监管机构提交的材料中列出的因素,包括Medexus最新的年度信息表以及管理层的讨论和分析。因此,不应过分依赖这些前瞻性陈述,这些陈述仅在本新闻发布之日作出。除了法律的特别要求外,Medexus没有义务更新任何前瞻性陈述以反映后续或其他方面的新信息。
Protected names and marks
受保护的名称和商标
This news release contains references to trademarks and other protected names and marks, including those belonging to other companies, persons, or entities. Solely for convenience, trademarks and other protected names and marks referred to in this news release may appear without the "", "", or other similar symbols. Each such reference should be read as though it appears with the relevant symbol. Any such references are not intended to indicate, in any way, that the holder or holders will not assert those rights to the fullest extent under applicable law.
本新闻稿包含对商标和其他受保护名称和商标的引用,包括属于其他公司、个人或实体的商标和其他受保护的名称和标记。仅为方便起见,本新闻稿中提及的商标和其他受保护的名称和商标在出现时可能没有 “”、“” 或其他类似符号。每项此类参考文献都应看作是带有相关符号的文字。任何此类提法均无意以任何方式表明持有人不会根据适用法律最大限度地主张这些权利。